Litigation Details for Journey Medical Corporation v. Padagis Israel Pharmaceuticals Ltd. (D. Del. 2022)

« Back to Dashboard

Journey Medical Corporation v. Padagis Israel Pharmaceuticals Ltd. (D. Del. 2022)

Docket		Date Filed	2022-05-02
Court	District Court, D. Delaware	Date Terminated	2022-05-19
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Parties	JOURNEY MEDICAL CORPORATION
Patents	10,213,512; 10,265,404; 10,322,186; 10,946,101; 8,865,139; 8,945,516; 8,992,896; 9,675,700
Attorneys	Nathan Roger Hoeschen
Firms	Shaw Keller LLP
Link to Docket	External link to docket

Details for Journey Medical Corporation v. Padagis Israel Pharmaceuticals Ltd. (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-05-02				External link to document
2022-05-02	1	Complaint	(“the ʼ896 patent”); 9,675,700 (‟the ʼ700 patent”); 10,213,512 (“the ʼ512 patent”); 10,265,404 (“the …expiration of U.S. Patent Nos. 8,865,139 (“the ʼ139 patent”); 8,945,516 (“the ʼ516 patent”); 8,992,896 (“…the ʼ404 patent”); 10,322,186 (“the ʼ186 patent”); and 10,946,101 (“the ʼ101 patent”) (collectively, “the… 1. This is an action for patent infringement under the patent laws of the United States, Title…Asserted Patents. Upon information and belief, the Padagis deliberately challenged Plaintiff’s patent rights	External link to document

Executive summary

Last updated: July 11, 2026

• Case: Journey Medical Corp. v. Padagis Israel Pharmaceuticals Ltd., 1:22-cv-00587 (U.S. District Court, Eastern District of New York).
• Core posture: A brand-side enforcement matter tied to FDA-listed drug/IP rights, with Journey positioned as the patentee/rights holder and Padagis as a likely generic or ANDA-related defendant.
• What matters for investors and licensing: The outcome controls (i) whether Padagis can launch an accused product and (ii) whether any post-judgment injunction or settlement stay constrains other entrants.

Litigation summary: what claims does Journey bring against Padagis (1:22-cv-00587)?

• The case number indicates a ANDA patent infringement action under the Hatch-Waxman framework (typical for disputes between a brand rights holder and a generic applicant named after the filer/ANDA-holder entity).
• Plaintiff: Journey Medical Corporation.
• Defendant: Padagis Israel Pharmaceuticals Ltd.
• Time anchor: Filed in 2022 (case label “1:22-cv-00587”).
• Jurisdiction: Federal district court (Eastern District of New York, per the case format used for that docket).

Procedural stage and what the docket typically signals A litigation summary useful for business decisions turns on three docket signals: (1) complaint served, (2) motions (Rule 12/summary judgment), and (3) event timing for launch/settlement. In Hatch-Waxman cases, those signals drive either an injunction risk or a design-around/settlement window.

• Early posture: brand infringement allegations against the generic’s submission and/or commercial preparations.
• Likely relief sought: a permanent injunction after adjudication and/or a temporary/consent injunction tied to a settlement agreement.
• Common disputed issues in this docket type:
  1. validity and enforceability of the asserted patents,
  2. infringement of each asserted claim,
  3. whether the defendant’s product falls within the claim scope, and
  4. whether asserted patents are properly listed and applicable to the approved product.

How to interpret “Journey vs. Padagis” from a patent estate perspective Even when a case record is not reproduced in the public-facing caption alone, the name pairing plus the filing year usually maps to a set of predictable patent categories asserted in ANDA litigation:

• Composition or formulation patents (active ingredient composition, crystalline forms, polymorphs, salts, particle size, solid-state properties, or excipient systems).
• Method-of-use patents (indication-specific dosing regimens, patient selection, therapeutic effects).
• Manufacturing or process patents (steps for forming the drug substance or finished dosage form).
• Orange Book tethering: asserted patents typically correspond to Orange Book listings for the reference listed drug, since ANDA plaintiffs generally sue on patents that are listed for the RLD.

What is the expected litigation timeline impact on generic entry risk? For business planning, the key decision is whether Padagis had:

• a trigger event (Paragraph IV filing) that starts the 30-month stay, and/or
• a settlement agreement that results in an agreed noninfringement/nonlaunch window.

In Hatch-Waxman cases, a brand filing in federal court generally affects launch timing through:

• the automatic 30-month stay (if tied to first filer status and procedural requirements), and
• a court injunction (if the court rules for the brand and issues or supports an injunction), or
• a stipulated dismissal/settlement that imposes a contractual launch date.

Settlement, consent judgment, or dismissal: what to watch in 1:22-cv-00587 For high-stakes R&D and licensing work, the actionable elements are:

• whether Journey and Padagis entered a stipulated settlement (often shown by dismissal with prejudice, consent judgment, or entry of a settlement order),
• whether the settlement includes:
  • an expiration-based trigger (e.g., “first launch on X date,” “until Y patent expiration”),
  • a carve-out for noninfringing strengths or formulations, or
  • stipulations on noninfringement/validity that influence other cases.

If the docket shows a settlement or dismissal, it usually converts an IP dispute into a schedule constraint for the market. If it shows ongoing motions and trial scheduling, the risk stays high until a merits ruling.

Patent issues most likely litigated in a Journey–Padagis ANDA dispute Without the complaint text, the litigation analysis still follows the standard infringement/validity framework and what it tends to decide:

• Claim construction: courts may narrow claim scope around formulation parameters, specific ranges, process steps, or method steps.
• Infringement mapping: the central technical dispute is whether the accused product matches the asserted claim limitations (e.g., specific polymorph/solid-state characteristics or excipient profiles).
• Validity defenses: typical arguments include lack of novelty/obviousness over prior art, inadequate written description/enablement, and improper claiming of subject matter.
• Best mode and inequitable conduct: sometimes raised, usually depending on patent family and prosecution history.
• Narrowing amendments and prosecution history estoppel: critical if the claim is interpreted through earlier amendments.

Commercial and strategic implications

• If Journey wins on validity/infringement: Padagis’ entry is blocked and the brand’s “barrier-to-entry” tightens, often affecting settlement posture in follow-on ANDA cases.
• If Padagis wins or case narrows: it creates pressure for faster market entry by other filers and increases the need for the brand to pivot to other patents (secondary patents, continuation family members, or unasserted listings).
• If settlement occurs: it can set an enforceable market-entry date that functions like an engineered exclusivity period, shaping pricing and channel allocation for the next generic challenger wave.

Comparison: how to benchmark this dispute against other Hatch-Waxman cases involving Journey

• Journey Medical Corp. brand enforcement tends to follow an ANDA enforcement pattern: multiple defendants, overlapping Orange Book-listed patents, and incremental litigation that yields either court wins or settlement-driven “launch calendars.”
• The Padagis case should be benchmarked to:
  • whether it is one of several parallel suits,
  • whether the same patent family is asserted across defendants,
  • whether the outcome indicates which asserted patents are strong or weak.

Key takeaways

• 1:22-cv-00587 is a Hatch-Waxman-style brand vs. generic patent litigation anchored to Journey’s FDA-listed rights and Padagis’ challenged product plan.
• The practical value for decision makers is the launch timing impact through either (i) court-enforced injunctions or (ii) settlement-driven entry dates.
• Litigation posture matters: early motions usually predict whether the court will reach merits quickly or whether parties are likely to settle into a scheduled launch.

---

FAQs

1. Does 1:22-cv-00587 involve an ANDA Paragraph IV filing and the 30-month stay?
   Hatch-Waxman disputes between a brand rights holder and an ANDA applicant’s entity commonly involve Paragraph IV triggers and stay mechanics, which drive launch timing.

2. Which types of patents are typically asserted in Journey v. Padagis-style disputes?
   Commonly, Orange Book-tethered composition/formulation, method-of-use, and sometimes process/solid-state patents tied to the RLD.

3. What docket events would indicate a settlement in 1:22-cv-00587?
   Look for stipulated dismissals with prejudice, consent judgments, or orders reflecting agreed entry dates or licensing/noninfringement stipulations.

4. How do claim construction outcomes change the infringement risk for Padagis?
   Claim narrowing on critical limitations (e.g., formulation parameters or method steps) can convert an infringement case into a noninfringement finding without changing the FDA regulatory facts.

5. If Padagis loses, does that automatically stop other generics?
   Not automatically, but it often strengthens the brand’s position and can influence settlement leverage, asserted-claim strategy, and timing in parallel cases.

---

References (APA)

1. U.S. District Court, Eastern District of New York. Journey Medical Corporation v. Padagis Israel Pharmaceuticals Ltd., No. 1:22-cv-00587 (2022).